Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Colorectal NeoplasmsIntestinal Neoplasms
- Interventions
- Drug: XELOX regimenDrug: mFOLFOX6 regimenDrug: FOLFIRI regimenDrug: mXELIRI regimenDrug: mIRIS regimen
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 77
- Registration Number
- NCT05193292
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Circulating EV Long RNA Profiles in SCLC
Not Applicable
Recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- Diagnostic Test: Blood sample collection
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT05191849
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
The Effect of Intervention With Probiotic K56 on Body Fat Reduction in Obese Subjects
Not Applicable
- Conditions
- Obesity
- Interventions
- Dietary Supplement: Lactobacillus paracasei K56Dietary Supplement: placebo
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT05192811
- Locations
- 🇨🇳
Hua Dong Hospital Affiliated to Fu Dan University, Shanghai, China
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
- Conditions
- Prostate CancerMetastatic DiseaseCastration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05188911
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression
Phase 2
Active, not recruiting
- Conditions
- Diffuse Large B-cell Lymphoma(DLBCL)
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 41
- Registration Number
- NCT05189197
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
Phase 2
Terminated
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 5
- Registration Number
- NCT05176925
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
Phase 2
Recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 136
- Registration Number
- NCT05174832
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
Phase 2
Active, not recruiting
- Conditions
- Atypical Endometrial HyperplasiaFertility IssuesObesity
- Interventions
- Device: levonorgestrel-releasing intrauterine system
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05172999
- Locations
- 🇨🇳
Obstetrics & Gynecology Hospital of Fudan University, Shanghai, Shanghai, China
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
Phase 2
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: Fruquintinib,Albumin Paclitaxel,Gemcitabine
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05168527
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Value of ctDNA in the Treatment of Multiple Primary Cancers
Phase 2
- Conditions
- Multiple Primary Cancers
- Interventions
- Genetic: ct-DNA guided therapy
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT05164510
- Locations
- 🇨🇳
Fudan University Shanghai Cencer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath